EXPLORE HUMVIRA THERAPEUTICS
With Swiss quality, Powered by Basel spirit, Landed in Wuhan
Committed to
autologous HSCs mediated ex vivo gene therapy
to address vastly unmet medical needs for a range of
rare hereditary disorders
MENDIVIRA GATEWAY
THINKING REVOLUTIONARILY FOR THE SOLUTION
​
Find the condition you would like to address
Harness decades of research and advancements of lentiviral mediated HSCs gene therapy to provide cures for a variety of genetic diseases through the approach of Medivira Gateway
SEVERE COMBINED IMMUNODEFIENCY
X-Linked SCID
ADA SCID
RAG-1 and RAG-2 Deficiency SCID
IL7R Deficiency SCID
Artemis SCID
JAK3 Deficiency SCID
Reticular Dysgenesis
MUCOPOLYSACCHARIDOSIS
Hurler Syndrome (MPSI)
Hunter Syndrome (MPSII)
Sanfilippo Syndrome (MPSIII A, B, C, and D)
Morquio Syndrome (MPSIV A, B)
Maroteaux Lamy Syndrome (MPSVI)
Sly Syndrome (MPSVII)
Hyaluronidase Deficiency (MPSIX)
SPHINGOLIPIDOSES
Fabry's Disease
Farber's Disease
Gaucher's Disease
Krabbe's Disease
Metachromatic Leukodystrophy
Niemann-Pick Disease
Tay-Sachs Disease
Sandhoff Disease
EX VIVO GENE THERAPY
One-time treatment, Life-long impact
Due to decades of clinical management of diverse blood disorders by applying allogeneic HSCs transplantation, the population of HSCs are chosen as the primary target for ex vivo gene therapy. Comparing allogeneic approach, engineered autologous HSCs transplantation exhibits multiple advantages:
Requiring no histocompatible donor
Eliminating the complications of GvHDs
Avoiding immunosuppressant lifelong administration
MENDIVIRA GATEWAY PIPELINES
Inherited rare diseases are individually
rare, but they have a collective frequency of 1 in 1000 live births world wide, making them a significant public health problem worldwide.
At Humvira Therapeutics, we provide a revolutionary gateway approach to tackle a range of blood&immune disorders and
metabolic aberrations.
